全球胰島素幫浦市場 - 2025 至 2033 年

2024 年全球胰島素幫浦市場規模達到 65.1 億美元，預計到 2033 年將達到 131.1 億美元，2025-2033 年預測期內的複合年成長率為 8.3%。

胰島素幫浦是一種小型的電腦化設備，它透過插入皮下的一根稱為導管的軟性管向糖尿病患者輸送胰島素。它們提供持續、穩定的胰島素流量（基礎胰島素），並且還可以在用餐時釋放更大劑量（推注胰島素）。這種輸送方法模仿了人體正常的胰島素釋放。

與每日多次注射相比，胰島素幫浦更準確，有助於更好地控制血糖水平。它們還可以減少所需針刺的次數並改善 A1c 水平。胰島素幫浦為飲食和運動提供了更大的靈活性，並可以幫助控制清晨高血糖，也稱為「黎明現象」。

對於血糖未達目標、胃輕癱、夜間或頻繁低血糖或懷孕的人來說，胰島素幫浦尤其有幫助。它們還可以與人體的血糖監測儀互動，幫助人體了解胰島素波動的模式，並可能根據這些資訊自動調整胰島素水平。這些因素推動了全球胰島素幫浦市場的擴張。

市場動態：

促進因素與約束因素

糖尿病及相關疾病盛行率高

糖尿病及其相關疾病的高盛行率極大地推動了全球胰島素幫浦市場的成長，預計將在整個市場預測期內保持成長。全球糖尿病及相關疾病的流行已成為一個緊迫的健康問題，截至 2021 年，約有 10.5% 的成年人口（約 5.366 億人）患有糖尿病。這種成長在城市地區和高收入國家尤其明顯，因為這些地區的生活方式因素顯著增加了糖尿病的風險。

人口老化，加上不良飲食、缺乏運動和肥胖率上升等生活方式的改變，是糖尿病病例激增的主要原因。這些因素會導致胰島素阻抗，尤其是第 2 型糖尿病，這種疾病佔全球所有糖尿病病例的 96% 左右。隨著確診人數不斷增加，對有效治療方案的需求也日益增加，包括先進的胰島素輸送系統。

胰島素幫浦已成為治療糖尿病的重要工具，與傳統的注射方法相比，它提供了一種更精確、更靈活的胰島素輸送方法。這些設備有助於持續皮下胰島素輸注，有助於穩定血糖水平並改善整體血糖控制。胰島素幫浦的普及率不斷提高，很大程度上是因為它能夠提高患者的生活品質並減輕日常糖尿病管理負擔。

此外，產業產品批准的關鍵參與者將推動全球胰島素幫浦市場的成長。例如，2023 年 5 月，FDA 批准 Beta Bionics iLet ACE 幫浦和 iLet 劑量決策軟體用於 6 歲及以上患有第 1 型糖尿病的個人。當與相容的連續血糖監測儀 (CGM) 一起使用時，這些組件會形成 iLet Bionic Pancreas，這是一種自動胰島素輸送 (AID) 系統。

此外，2023 年 9 月，Emecta 的一次性胰島素輸送系統獲得了 FDA 510(k) 批准，這是一種專為患有 1 型和 2 型糖尿病的成年人設計的貼片幫浦。此「開迴路」系統採用無管設計，配備 300 個單位的胰島素儲存器。該設計基於 2 型糖尿病患者和醫療保健提供者的回饋。它可以提供長達三天的可調式基礎胰島素和餐時胰島素。所有這些因素都要求全球胰島素幫浦市場的發展。此外，對技術進步的需求不斷成長，促進了全球胰島素幫浦市場的擴張。

胰島素幫浦成本高昂

胰島素幫浦的高成本是許多醣尿病患者控制病情的一大障礙。如果沒有保險，新的胰島素幫浦的價格可能高達約 6,000 美元，另外每年的耗材額外費用在 3,000 美元至 6,000 美元之間。這些費用可能因泵浦的功能以及對電池和感測器等消耗品的持續需求而異。對於那些沒有足夠保險的人來說，經濟負擔可能是巨大的，因為他們還必須單獨支付透過該設備輸送的胰島素費用，而美敦力胰島素幫浦目前的價格為 8,574 美元。

胰島素幫浦和相關用品的高成本仍然是許多醣尿病患者面臨的巨大障礙，影響了他們獲得基本治療選擇和有效管理病情的能力。因此，上述因素可能會限制全球胰島素幫浦市場的潛在成長。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動態

• 影響因素
  • 驅動程式
    • 糖尿病及相關疾病盛行率高
  • 限制
    • 胰島素幫浦成本高昂
  • 機會
  • 影響分析

第5章：戰略洞察與產業展望

• 市場領導者和先驅者
• 新興先鋒和傑出參與者
• 擁有最大、最暢銷品牌的成熟領導者
• 擁有成熟產品的市場領導者
• CXO 觀點
• 最新進展與突破
• 案例研究/正在進行的研究
• 監管和報銷情況
• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東和非洲
• 波特五力分析
• 供應鏈分析
• 專利分析
• SWOT 分析
• 未滿足的需求和差距
• 市場進入和擴張的推薦策略
• 情境分析：最佳情況、基本情況和最壞情況預測
• 定價分析和價格動態
• 關鍵意見領袖

第 6 章：按類型

• 貼片泵浦
• 繫留泵浦

第 7 章：按產品

• 迷你醫療
• 精準檢查
• 串聯
• Omnipod
• 我的生活Omnipod
• 其他

第 8 章：按配件

• 胰島素儲液器或胰島素筒
• 胰島素注射裝置
• 電池

第9章：按疾病指徵

• 1 型糖尿病
• 2 型糖尿病

第 10 章：按最終用戶

• 醫院
• 專科診所
• 居家護理
• 其他

第 11 章：按地區

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地區
• 亞太
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 中東和非洲

第 12 章：競爭格局

• 競爭格局
• 市場定位/佔有率分析
• 併購分析

第 13 章：公司簡介

• Medtronic
• 公司概況
• 產品組合
  • 產品描述
  • 產品關鍵績效指標 (KPI)
  • 歷史和預測產品銷售量
  • 產品銷售量
• 財務概覽
  • 公司收入
  • 地區收入佔有率
  • 收入預測
• 主要進展
  • 合併與收購
  • 關鍵產品開發活動
  • 監管部門批准等
• SWOT 分析
• Roche
• Tandem Diabetes Care, Inc.
• Insulet Corporation.
• Ypsomed AG
• Novo Nordisk
• SOOIL Developments Co., Ltd
• Johnson & Johnson Services, Inc.

第 14 章：附錄

The global insulin pump market reached US$ 6.51 billion in 2024 and is expected to reach US$ 13.11 billion by 2033, growing at a CAGR of 8.3 % during the forecast period 2025-2033.

Insulin pumps are small, computerized devices that deliver insulin to people with diabetes via a flexible tube called a catheter, which is inserted under the skin. They offer a continuous, steady flow of insulin (basal) and can also release larger doses (bolus) around mealtime. This delivery method mimics the body's normal release of insulin.

Compared to multiple daily injections, insulin pumps can be more accurate and help to better manage blood sugar levels. They may also reduce the number of needle sticks required and improve A1c levels. Insulin pumps offer more flexibility with diet and exercise and can help manage early morning high blood sugar, also called the "dawn phenomenon".

Insulin pumps can be especially helpful for those who are not meeting blood glucose targets, have gastroparesis, experience nocturnal or frequent low blood sugar levels, or are pregnant. They can also interact with a person's blood glucose monitor to help them understand the patterns of their insulin swings and may be able to automatically adjust insulin levels based on this information. These factors have driven the global insulin pump market expansion.

Market Dynamics: Drivers & Restraints

High Prevalence of Diabetes and Associated Disorders

The high prevalence of diabetes and associated disorders is significantly driving the growth of the global insulin pump market and is expected to drive throughout the market forecast period. The global prevalence of diabetes and related disorders has become a pressing health issue, with approximately 10.5% of the adult population, or around 536.6 million individuals, living with diabetes as of 2021. Projections indicate that this number could escalate to 783 million by 2045, underscoring a growing epidemic that demands effective management strategies. This increase is particularly evident in urban areas and high-income countries, where lifestyle factors significantly contribute to the risk of developing diabetes.

Aging populations, coupled with lifestyle changes such as poor diet, physical inactivity, and rising obesity rates, are primary drivers behind the surge in diabetes cases. These factors lead to insulin resistance, especially in type 2 diabetes, which accounts for about 96% of all diabetes cases globally. As the number of diagnosed individuals continues to rise, there is an increasing demand for effective treatment options, including advanced insulin delivery systems.

Insulin pumps have become essential tools for managing diabetes, offering a more precise and flexible method of insulin delivery compared to traditional injection methods. These devices facilitate continuous subcutaneous insulin infusion, helping to stabilize blood glucose levels and improve overall glycemic control. The growing adoption of insulin pumps is largely driven by their ability to enhance patients' quality of life and reduce the daily burden of diabetes management.

Additionally, key players in the industry product approvals that would drive this global insulin pump market growth. For instance, in May 2023, the FDA cleared the Beta Bionics iLet ACE Pump and iLet Dosing Decision Software for individuals aged six and older with type 1 diabetes. When used with a compatible continuous glucose monitor (CGM), these components form the iLet Bionic Pancreas, an automated insulin delivery (AID) system.

Also, in In September 2023, Embecta, received FDA 510(k) clearance for its disposable insulin delivery system, a patch pump designed for adults with type 1 and type 2 diabetes. This "open-loop" system features a tubeless design with a 300-unit insulin reservoir. The design was based on feedback from people with type 2 diabetes and healthcare providers. It delivers adjustable basal and bolus insulin for up to three days. All these factors demand the global insulin pump market. Moreover, the rising demand for technological advancements contributes to the global insulin pump market expansion.

High Cost of Insulin Pumps

The high cost of insulin pumps is a significant barrier for many individuals managing diabetes. Without insurance, the price of a new insulin pump can reach approximately $6,000, with additional annual costs for supplies ranging from $3,000 to $6,000. These expenses can vary based on the pump's features and the ongoing need for consumables like batteries and sensors. For those without adequate insurance coverage, the financial burden can be overwhelming, as they must also pay separately for the insulin delivered through the device, and a Medtronic insulin pump is currently priced at $8,574.

The high cost of insulin pumps and associated supplies remains a formidable obstacle for many individuals with diabetes, impacting their ability to access essential treatment options and effectively manage their condition. Thus, the above factors could be limiting the global insulin pump market's potential growth.

Segment Analysis

The global insulin pump market is segmented based on type, product, accessories, disease indication, end-user, and region.

Type:

The tethered pumps segment is expected to dominate the global insulin pump market share

The tethered pumps segment holds a major portion of the global insulin pump market share and is expected to continue to hold a significant portion of the global insulin pump market share during the forecast period. Tethered insulin pumps are a significant part of the diabetes management market, providing a more precise and customizable insulin delivery system. These devices use a catheter connected to a pump worn by the user, delivering insulin through an infusion set placed under the skin, typically in the abdomen or thigh.

Tethered pumps allow users to adjust basal rates (background insulin) and bolus doses (mealtime insulin), which can improve blood glucose control, especially for individuals with Type 1 diabetes or Type 2 diabetes who struggle with stable blood sugar levels using traditional injections. Insulin pumps, including tethered pumps, offer significant advantages over traditional insulin therapy by delivering continuous basal insulin and on-demand bolus doses, providing steadier and more consistent insulin flow. This helps users achieve better blood glucose control, reducing A1C levels and minimizing the risk of hypoglycemia.

Additionally, key players in the industry have innovative product launches that would propel this segment's growth in the global insulin pump market. For instance, in December 2023, Tandem Diabetes Care launched updated t: slim X2 insulin pump software in the U.S. that integrates with the Dexcom G7 Continuous Glucose Monitoring (CGM) system4. The t: slim X2 pump, when paired with Control-IQ technology, stands out as the only automated insulin delivery (AID) system that works with Dexcom's G7 CGM. This integration builds upon nearly a decade of collaboration and previous integrations of Dexcom CGM systems. These factors have solidified the segment's position in the global insulin pump market.

Geographical Analysis

North America is expected to hold a significant position in the global insulin pump market share

North America holds a substantial position in the global insulin pump market and is expected to hold most of the market share. The insulin pump market in North America has seen significant growth, driven by the rising prevalence of diabetes, advancements in technology, and increased awareness of insulin pump benefits. This growth is fueled by the increasing number of diabetes cases, especially Type 1 diabetes, and the shift from traditional insulin therapies to more advanced insulin pumps for better glucose control. For instance, in 2021, approximately 38.4 million Americans, representing 11.6% of the population, were living with diabetes. Among these individuals, 29.7 million had received a formal diagnosis, while 8.7 million remained undiagnosed.

Key factors driving the demand for insulin pumps include the growing diabetes epidemic, technological improvements such as integration with continuous glucose monitoring (CGM), and enhanced insurance coverage for these devices. As healthcare spending rises and awareness about diabetes management increases, insulin pumps are becoming more accessible, further boosting market growth.

Additionally, a major of key players' presence, well-advanced healthcare infrastructure, and innovative product launches & approvals would drive this global insulin pump market growth. For instance, in February 2024, Tandem Diabetes Care launched the Tandem Mobi in the U.S., which they claim is the world's smallest durable automated insulin delivery system. With this launch, they are implementing a strategy to provide a diverse range of durable insulin pumps, offering users more choices and innovative options for wearability.

Also, in August 2024, Insulet Corporation announced that its Omnipod 5 Automated Insulin Delivery System is now FDA-cleared for use by adults with type 2 diabetes, aged 18 and older. This marks a significant milestone as the Omnipod 5 becomes the first and only automated insulin delivery (AID) system approved for managing both type 1 and type 2 diabetes. Thus, the above factors are consolidating the region's position as a dominant force in the global insulin pump market.

Asia Pacific is growing at the fastest pace in the global insulin pump market share

Asia Pacific holds the fastest pace in the global insulin pump market and is expected to hold most of the market share. The insulin pump market in the Asia-Pacific (APAC) region has been growing rapidly, driven by a rising diabetic population, increased healthcare investments, and advancements in insulin delivery technology. This growth is largely fueled by the increasing prevalence of diabetes in countries such as China, India, and Japan, alongside a shift towards more advanced diabetes management solutions.

Globally, approximately 1 in 8 adults around 206 million people are living with diabetes. The Western Pacific Region is significantly impacted, accounting for over 38% of the total adult diabetes population. Notably, China alone represents 1 in 4 adults with diabetes worldwide. Alarmingly, more than 53% of these individuals remain undiagnosed.

Diabetes is a major health concern, resulting in 2.3 million deaths in 2021, the highest among all regions reported by the International Diabetes Federation (IDF). The economic burden of diabetes is substantial, with global expenditures reaching USD 241 billion in 2021, which constitutes 25% of total diabetes-related spending. Additionally, about 1 in 7 live births are affected by hyperglycemia during pregnancy, highlighting the widespread impact of this condition on maternal and child health.

Technological advancements, such as continuous glucose monitoring (CGM) integration and user-friendly features, are also making insulin pumps more attractive. Additionally, higher healthcare spending, better insurance coverage, and government initiatives are improving access to insulin pumps, while growing public awareness is expected to further boost market growth in the coming years.

Additionally, key players' strategies such as partnerships & collaborations, and product launches would drive this global insulin pump market growth. For instance, in October 2023, Terumo Corporation and Dexcom, Inc. agreed to end their distribution agreement for Dexcom's Continuous Glucose Monitoring Systems (CGM) in Japan. This decision aligns with Dexcom's new marketing strategy to transition from indirect distribution to direct sales in key markets, excluding the U.S.

Also, in March 2022, Medtronic India launched the MiniMed 780G system, a next-generation closed-loop insulin pump designed for managing type 1 diabetes in individuals aged 7 to 80. This system automates the delivery of both basal insulin and correction boluses every five minutes, helping patients avoid high and low glucose levels with greater ease. The MiniMed 780G system incorporates SmartGuard technology to automatically adjust insulin delivery and correct high glucose levels, while also working to prevent low glucose levels. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global insulin pump market.

Competitive Landscape

The major global players in the insulin Pump market include Medtronic, Roche, Tandem Diabetes Care, Inc., Insulet Corporation., Ypsomed AG, Novo Nordisk, SOOIL Developments Co., Ltd, and Johnson & Johnson Services, Inc. among others.

Key Developments

• In October 2024, Luna Diabetes launched a pivotal trial for its innovative insulin delivery system, known as the Luna, which is touted as the world's smallest insulin patch pump. This system aims to revolutionize nighttime glucose management by delivering micro-doses of insulin while users sleep.
• In September 2024, Modular Medical announced that it had received FDA clearance for its MODD1 insulin pump, which is intended for use by adults with Type 1 and Type 2 diabetes. The company expects to launch the product in early 2025.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global insulin Pump market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Product
• 3.3. Snippet by Accessories
• 3.4. Snippet by Disease Indication
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. High Prevalence of Diabetes and Associated Disorders
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Insulin Pumps
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
• 5.2. Emerging Pioneers and Prominent Players
• 5.3. Established leaders with largest largest-selling Brand
• 5.4. Market leaders with established Product
• 5.5. CXO Perspectives
• 5.6. Latest Developments and Breakthroughs
• 5.7. Case Studies/Ongoing Research
• 5.8. Regulatory and Reimbursement Landscape
• 5.9. North America
• 5.10. Europe
• 5.11. Asia Pacific
• 5.12. Latin America
• 5.13. Middle East & Africa
• 5.14. Porter's Five Force Analysis
• 5.15. Supply Chain Analysis
• 5.16. Patent Analysis
• 5.17. SWOT Analysis
• 5.18. Unmet Needs and Gaps
• 5.19. Recommended Strategies for Market Entry and Expansion
• 5.20. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.21. Pricing Analysis and Price Dynamics
• 5.22. Key Opinion Leaders

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Patch Pumps *
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Tethered Pumps

7. By Product

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.1.2. Market Attractiveness Index, By Product
• 7.2. MiniMed*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Accu-Chek
• 7.4. Tandem
• 7.5. Omnipod
• 7.6. My Life Omnipod
• 7.7. Others

8. By Accessories

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Accessories
  • 8.1.2. Market Attractiveness Index, By Accessories
• 8.2. Insulin Reservoirs or Cartridges*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Insulin Set Insertion Devices
• 8.4. Batteries

9. By Disease Indication

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 9.1.2. Market Attractiveness Index, By Disease Indication
• 9.2. Type 1 Diabetes*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Type 2 Diabetes

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Specialty Clinics
• 10.4. Homecare
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Accessories
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Accessories
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Accessories
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Accessories
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Accessories
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Medtronic*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio
    • 13.1.2.1. Product Description
    • 13.1.2.2. Product Key Performance Indicators (KPIs)
    • 13.1.2.3. Historic and Forecasted Product Sales
    • 13.1.2.4. Product Sales Volume
  • 13.1.3. Financial Overview
    • 13.1.3.1. Company Revenue's
    • 13.1.3.2. Geographical Revenue Shares
    • 13.1.3.3. Revenue Forecasts
  • 13.1.4. Key Developments
    • 13.1.4.1. Mergers & Acquisitions
    • 13.1.4.2. Key Product Development Activities
    • 13.1.4.3. Regulatory Approvals etc.
  • 13.1.5. SWOT Analysis
• 13.2. Roche
• 13.3. Tandem Diabetes Care, Inc.
• 13.4. Insulet Corporation.
• 13.5. Ypsomed AG
• 13.6. Novo Nordisk
• 13.7. SOOIL Developments Co., Ltd
• 13.8. Johnson & Johnson Services, Inc.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us